RO 749-9790/F02-02

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

RET fusion−positiveSolid tumorsmetastatic Non-Small Cell Lung Cancer

Phase 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruitingCTIS2023-507418-28-00

F. Hoffmann-La Roche AGSolid tumors

Start: 2021-03-15Target: 407Updated: 2025-12-09

Phase 3

A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer

CompletedCTIS2023-505035-12-00

F. Hoffmann-La Roche AGmetastatic Non-Small Cell Lung Cancer, RET fusion−positive

Start: 2020-06-12End: 2025-01-27Target: 140Updated: 2025-03-03